precision therapies for
eye disease

Rewriting the genetic code of Inherited Retinal Diseases — for the people who live it

Born from a collaboration between Australia's foremost eye research institution CERA and MedicVision AI, an AI-driven ophthalmology innovator, Adara Bio brings together world-class science, deep clinical expertise, and a bold commercial vision.

We exist for the patients who have been told there is no cure — because we believe that is about to change.

THE OPPORTUNITY IN NUMBERS

Addressing an Unmet Need in Inherited Retinal Diseases

01

4 Million

Patients worldwide

Over 4 million individuals suffer for Inherited Retinal Diseases, representing the leading cause of blindness among working-age adults.

02

300+

Genetic targets

The vast genetic diversity of IRDs has bottlenecked traditional gene therapies. Adara’s scalable platform is built to overcome this by targeting multiple mutations with one core editor.

03

24%

Point mutation coverage

The EDITRA™ platform is capable of correcting up to 24% of the known point mutations responsible for causing Inherited Retinal Diseases worldwide.

04

Gene Size Independent

Overcoming the Cargo Limit

Large-gene indications like USH2A and EYS exceed standard viral vector capacities. Because Adara edits RNA rather than replacing whole genes, our platform is completely independent of gene size.

Shereen Tan

Director & COO

Commercial leader with expertise in biotech, business development and strategy.

Jitto Arulampalam

Executive Chairman

Experienced executive and investor. Co-founder, RedOwl Pty Ltd.

Rick Liu

Founder & CSO

Founder of Adara Bio and leader in genetic engineering research.

OUR PEOPLE

Complementary leadership.
Proven concept-to-clinic experience

Stanley Chang

Director

Chairman and executive with experience in drug development, vaccines, diagnostics and ophthalmic therapeutics.

Darren Kelly

Director

Biotech CEO and founder with proven concept-to-acquisition experience.

Emily Lee

Alternate Director

Business leader with expertise in cross-border transactions and corporate finance.

Keith Martin

CMO

Ophthalmologist, gene therapy leader and biotech founder with proven translational experience.

OUR INVESTORS, PARTNERS & SPONSERS

OUR TECHNOLOGY

One Platform.
Many Corrections.

Adara Bio's RNA re-writing platform, EDITRA™ is designed to address the genetic diversity of Inherited Retinal Diseases. By precisely correcting disease-causing mutations at the RNA level, EDITRA™ provides a flexible and adaptable approach that can be programmed for different genetic targets while avoiding permanent changes to DNA.

The platform is designed to enable the development of a scalable pipeline of precision therapies for retinal diseases with significant unmet medical need.